ArticleNature metabolism2023
Writing and erasing ceramides to alter liver disease.
Mariah Weber-Stout, Scott A Summers, William L Holland
Open access · greenAbstract readComment
In one paragraphArticle in Nature metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
3 authors at 1 institution in 1 country.
Mariah Weber-StoutDepartment of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT, USA.
University of Utah · US
Funding
Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7MDihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR44DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2018 to 2022
$4.7MLiver-islet and intra-islet cross talk in alpha cell hyperplasia and beta cell regenerationR01DK112826 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2017 to 2025
$3.4MThe Role of Ceramides in Skeletal MuscleR01DK115824 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2018 to 2021
$2.6MThe Role of Ceramides in the Intestinal Stem CellR01DK131609 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI EDGAR, BRUCE ALEXANDER, SUMMERS, SCOTT A · 2021 to 2025
$2.5MThe Role of Ceramides in the Pancreatic Beta CellR01DK130296 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLLAND, WILLIAM L, SUMMERS, SCOTT A · 2022 to 2025
$2.2MTargeting a Ceramide Double Bond to Treat Cardiometabolic DisordersR01DK122001 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2019 to 2022
$1.9MThe role of sphingolipids in the pancreatic beta cellR21DK073181 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2006 to 2007
$482kDihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR43DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2017 to 2017
$225kNCI NIH HHS U01 CA272529NIDDK NIH HHS R01 DK112826NIDDK NIH HHS R01 DK115824NIDDK NIH HHS R01 DK122001NIDDK NIH HHS R01 DK130296NIDDK NIH HHS R01 DK131609NIDDK NIH HHS R21 DK073181NIDDK NIH HHS R43 DK116450NIDDK NIH HHS R44 DK116450
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
CeramidesLiver DiseasesHumansWritingCeramides
Identifiers
PMID37188817
PMCPMC10906105
OpenAlexW4376609664
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390